BSE in NORDAMERIKA >>>>> Erste Fälle<<<<<<< - 500 Beiträge pro Seite

[22.09.94]

Hallo Leute,

heute nacht habe ich auf "B5 aktuell" einen Bericht über
BSE-Fälle bei Rotwild in Nordamerika gehört.

Laut Schätzungen von Experten könnten derzeit
ca. 10-15 Prozent des Rotwildbestandes befallen sein.

Übertragung auf andere Tierarten scheint möglich.

Wie ist Eurofins in Nordamerika positioniert ?

Riesenmarkt für Eurofins ?

Wer kann mir weiterhelfen ?

MFG

[blindfisch]

was für ein hirsch bist du denn.....?

gruß

bf

[22.09.94]

Hallo Leute,

hat noch jemand den Bericht auf "B 5 aktuell" mitbekommen.

Konnte akustisch nicht alle Einzelheiten verstehen.

MFG

[NOMORESECRETS]

In USA befasst sich IDEXX schon laenger mit BSE, siehe Artikel unten. Vor ca. 2 Wochen wurde das wieder einmal in der "Welt" erwaehnt. IDEXX verwendet diesbezueglich eine Lizenz der (noch nicht?) boersennotierten Caprion, siehe unten.

IDEXX befasst sich jedoch auch mit anderen interessanten Maerkten, wie z.B. Geraeten zur Ueberwachung der Wasserqualitaet, Medikamente/ Medizintechnik fuer Haustiere, Milchschnelltest-Geraete usw.

IDXX ist in den USA gut zu kaufen, hier ist das Volumen zu gering, an vielen Tagen kein Umsatz.

Wachstum ca. 30 % im Jahr, mit und ohne BSE.

KGV 2001 18.1


Chartechnisch gibt es eine sehr starke Unterstuetzung bei 20USD sowie einen Widerstand bei 28 USD. Derzeit haelt sich der Kurs in der Naehe der unteren Unterstuetzung auf.





>>>>>>>



IDEXX Laboratories, Inc.: Caprion has established a collaboration with IDEXX (IDXX:NASDAQ) a global leader in veterinary pharmaceuticals, for the development of Caprion`s proprietary reagents for the diagnosis of Mad Cow Disease and other Transmissible Spongiform Encephalopathies.


>>>>>>>


Caprion works on mad cow diagnostic tool, wins funds

(all figures in U.S. dollars) By Ian Karleff

TORONTO, Dec 5 (Reuters) - Canada`s Caprion Pharmaceuticals is developing ways to detect the presence of mad cow disease in live animals, a prospect that lured more than $33 million into the company`s coffers on Tuesday in a private placement.

The cash will let Caprion develop a database of proteins at the sub-cellular level, allowing drug developers to pinpoint which proteins are responsible for a particular disease.

Yorkton Securities was the lead underwriter for the private placement, while venture capital firm Ventures West contributed to the oversubscribed offering, following on its prior support for Caprion.

The first protein discovered by Caprion, the prion protein, is licensed to IDEXX Laboratories Inc. <IDXX.O>, and the companies hope their collaboration will lead to a veterinary diagnostic tool to determine if a live animal carries mad cow disease. Previous tests were carried out after animals died or were slaughtered.

Mad cow disease, or bovine spongiform encephalopathy (BSE) cow disease, is a brain wasting disease whose human form has killed more than 80 people in Britain and two in France.

"We developed a means to detect the infectious form of the protein, which is behind mad cow disease and developed an antibody for that detection," Caprion Chief Executive Lloyd Segal told Reuters.

"Now we take the brain tissue from dead animals to make a diagnosis of mad cow. There is currently no way to draw blood from a live cow and say `Ah, this cow has mad cow disease.` This is costing governments millions of dollars," added Segal.

Caprion has also developed an early stage detection marker for Alzheimers disease that it hopes to license to a drug developer for advancement into a diagnostic product.

Segal said Caprion should be generating royalty revenues based on its protein discoveries within three years. Depending on market conditions the firm hopes to sell shares in an initial public offering next year.

Nancy Harrison, senior vice-president at venture capital firm Ventures West, said Caprion`s database of disease causing proteins will within the next five years form a valuable tool for drug developers interested in knowing how proteins react with each other in the body.

"What these guys can do on a mass scale is identify proteins in different compartments...and are able to do in proteomics (the study of understanding the role of proteins in disease) what others can`t," said Harrison.

((Reuters Toronto Bureau 416-941-8102 e-mail [e-mail]))

REUTERS

Rtr 18:28 12-05-00




>>>>>>




Caprion raises $52.5 Million in largest private financing of an independent Canadian biotech company

Venture and institutional investor`s rally around company`s cell mapping and proteomics vision for the treatment of disease

Montreal, Quebec, December 5, 2000 - Caprion Pharmaceuticals today announced that it has raised $52.5 million in the largest ever private placement for an independent Canadian biotechnology company. Managed by Yorkton Securities, lead investors included Ventures West which recognized the company`s enormous and unique potential to detect proteins at the sub-cellular level and accelerate the development of new drugs and diagnostic tools for disease treatment and Fidelity Management & Research Company, on behalf of funds and accounts managed by it. Caprion`s current programs include the first diagnostic products for BSE (Mad Cow Disease) and its human strain Creutzfeldt-Jacob`s Disease (vCJD), as well as earlier stage diagnostics and therapeutics programs in Alzheimer`s Disease (AD) and Amyotrophic Lateral Sclerosis (ALS).

With the sequencing of the human genome now complete, the discovery of the proteome ?the nature and function of all proteins? stands as the next important challenge for the pharmaceutical industry. Caprion is applying proprietary processes in sub-cellular biology together with large-scale mass spectrometry to create a detailed base of knowledge and understanding of the proteome.

Caprion`s protein cell mapping efforts will result in a comprehensive, integrated database of proteomics information for cell types under normal and diseased conditions. The company and its partners will be able to use this information to understand the protein changes underlying the pathology of diseases and develop diagnostic and therapeutic products and treatment strategies based on these findings.

?This is an important day for the entire Canadian biotech sector,? says Lloyd Segal, President and CEO, Caprion. ?This financing puts Caprion on par with key global competitors in proteomics. Historically, efforts of this scale only happen in the US - today, however, a blue-chip collection of US and Canadian financial institutions and venture investors have provided us with the critical capital resources we need to compete globally and impact the pharmaceutical drug development industry with some exciting new technologies and innovation.?

According to Ezra Lwowski, biotechnology analyst at Yorkton: ?Caprion is the only company to our knowledge that can anchor the biochemistry of proteins to cell physiology on a massive scale. This added dimension provides a higher degree of resolution to the function of proteins within a cell, which makes Caprion a unique and valuable source of drug target opportunities.? Coupled with the dynamism of the Caprion management team, ?We were delighted to be able to increase the size of the deal based upon strong demand from leading North American institutional investors and dedicated high science venture capital funds, despite very weak overall market conditions.? says Mitchell Greenspoon, Executive Vice-President of Yorkton.

Ventures West backs Caprion as sole Canadian Venture Capital Investor

Ventures West is the sole Canadian venture capital investor and has been a strategic partner since Caprion`s inception. With $10.5 million invested in this round, the company`s total commitment to date is $13.5 million. As a strategic partner, Ventures West provides both capital, mentorship and strategic management support to Caprion`s executive team as it builds for rapid growth, continued capital investments and business development.

?Ventures West has always looked for Canadian companies that have the potential to define or lead an emerging industry sector, we call it the `go big or go home` philosophy,? says Nancy Harrison, partner, Ventures West. ?We believe that Caprion is in the position to lead the advancement of proteome sciences and are committed to partnering with this company over the long term as it grows and matures to become a Canadian-based, world-class leader in biotech.?


About Caprion

Caprion Pharmaceuticals Inc. is a proteomics company applying proprietary processes in resolving sub-cellular protein information - Cell Mapping - to understand the role of proteins in disease. Caprion provides Cell Map services to major biopharmaceutical companies to increase the speed and efficiency of early stage drug discovery and to develop its own diagnostic and therapeutic products, which currently include the first blood screening products for Mad Cow Disease and its human equivalents. Caprion has recently announced an investment of $11.5 million by Micromass Inc, Manchester, UK, a wholly owned subsidiary of Waters Corporation (WAT:NYSE) for the application of Micromass` mass spectrometry technologies to Caprion`s high throughput proteomics. For more information please visit our Web site at www.caprion.com.

About Yorkton

Yorkton Securities is Canada`s leading technology investment bank with offices across Canada, London and Chicago. Yorkton is the market share leader in underwriting Canadian Internet & e-business, Technology and Healthcare companies. Yorkton is active in all aspects of the capital markets, including private and public equity financing, equity research, institutional sales & trading, private client services, strategic advisory and mergers & acquisitions. Over the past five years, Yorkton has participated in 442 deals for knowledge based companies, raising in excess of $14.5 billion. For more information visit our Web site at www.yorkton.com.

About Ventures West

Ventures West is a private, professional venture capital management group, which manages over $400 million in risk capital. Established in 1968, Ventures West is one of Canada`s preeminent technology investment organizations. It invests in young technology companies across Canada from offices in Vancouver, Toronto and Ottawa. Ventures West`s investment focus is on companies in the telecommunications, e-business, biotech, wireless and energy technology sectors. Examples of portfolio companies include: Angiotech Pharmaceuticals Inc., Caprion Pharmaceuticals Inc., FloNetwork Inc., Novatel Wireless, Pivotal Corporation, Quest Air Technologies Inc., and Zenastra Photonics Inc. For further information visit www.ventureswest.com.

For more media inquiries call:

Andrew Bowins
Maverick Public Relations Inc.
[phone]
[e-mail]

Lloyd M. Segal
President & CEO
Caprion Pharmaceuticals Inc.
[phone]
[e-mail]

Ezra Lwowski Ph.D. M.B.A
Senior Biotech Analyst,
Yorkton Securities Inc.
[phone]
[e-mail]







Westbrook, Maine - August 30, 1999 - IDEXX Laboratories, Inc. and Caprion Pharmaceuticals, Inc. announced today that they will collaborate on the development of Caprion?s proprietary reagents for the diagnosis of Mad Cow Disease and other Transmissible Spongiform Encephalopathies (TSEs).

IDEXX will receive exclusive global rights for veterinary applications in diagnostics and therapeutics, while Caprion retains all rights to human diagnostic and therapeutic applications. IDEXX has made an equity investment in Caprion, and will support research at Caprion?s Montreal-based laboratories. IDEXX will also conduct development work in its laboratory in Westbrook, Maine, contributing expertise in diagnostic test development. IDEXX will market veterinary products resulting from the collaboration and pay Caprion royalties on product sales.

The goal of the collaboration is development of a rapid diagnostic for detecting Bovine Spongiform Encephalopathy (BSE), commonly known as Mad Cow Disease, in live cattle. Current detection methods require brain tissue samples from slaughtered animals. A live animal diagnostic would allow governments and producers to implement cost-effective surveillance programs to protect and validate disease-free status.

Abnormal prion proteins, thought to trigger BSE, are also associated with the human condition, Creutzfeldt-Jakob Disease (CJD). The recent emergence of "new variant CJD" in the United Kingdom and France is believed to be linked to BSE-diseased cattle.

"BSE and other TSEs are important health concerns," stated Dr. Erwin Workman, executive vice president and chief scientific officer of IDEXX. "The veterinary market currently has no proven diagnostic for BSE in live cattle. Caprion?s reagents and skills in the prion field position us well to take on this important challenge in veterinary health care."

"IDEXX?s depth in product development and in marketing and sales of advanced veterinary diagnostic technology makes them an ideal partner for Caprion," stated Lloyd M. Segal, president and CEO of Caprion. "Their ability to transform sound technologies into marketable products is well proven."

IDEXX Laboratories, Inc. is a world leader in providing diagnostic, detection and information systems for veterinary, food and water testing applications. The Company also operates an international network of veterinary reference laboratories and is a leader in the veterinary software and informatics market. IDEXX entered the veterinary pharmaceuticals market with its acquisition of Blue Ridge Pharmaceuticals in October 1998. Headquartered in Westbrook, Maine, IDEXX employs more than 2,000 people and offers over 350 products to customers in more than 50 countries.

Caprion Pharmaceuticals Inc. is a privately held Montreal-based biopharmaceutical company exploiting "shape-shifting" proteins as targets for diagnostics and therapeutic intervention. Prion proteins are the best-known shape-shifters and are the focus of Caprion?s earliest products. Caprion is using its expertise in protein conformational change as a key interventional target in the development of neurological and immunological therapies.

Contact:
Denise Sposato
207-856-0322
IDEXX Laboratories, Inc.
One IDEXX Drive
Westbrook, Maine 04092
Fax: [phone]
[e-mail]

Lloyd M. Segal
514-940-3604
Caprion Pharmaceuticals, Inc.
5375 Pare Street, Suite 201
Montreal, Qc, Canada H4P 1P7
Fax: [phone]
www.caprion.com

[lecu68]

@NOMORESECRETS

du hättest dir das ganze sparen können. Liest eh keiner.

lecu68